



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION




BDTX-189

Item No. 33932

CAS Registry No.: 2414572-47-5
Formal Name: N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-7-[2-(4-morpholinyl)ethoxy]-6-quinazolinyl]-2-propenamide

MF: $C_{29}H_{29}ClN_6O_4$
FW: 561.0
Purity: $\geq 98\%$
UV/Vis.: λ_{max} : 253, 347 nm
Supplied as: A solid
Storage: $-20^{\circ}C$
Stability: ≥ 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BDTX-189 is supplied as a solid. A stock solution may be made by dissolving the BDTX-189 in the solvent of choice, which should be purged with an inert gas. BDTX-189 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of BDTX-189 in these solvents is approximately 1 mg/ml.

BDTX-189 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BDTX-189 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BDTX-189 has a solubility of approximately 0.30 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BDTX-189 is an inhibitor of wild-type and mutant EGFR and HER2 ($IC_{50}s = \leq 30-500$ and $\leq 10-100$ nM, respectively).¹ *In vivo*, BDTX-189 (30 and 50 mg/kg, twice daily) reduces tumor growth in a CUTO14 non-small cell lung cancer (NSCLC) mouse xenograft model.

Reference

1. Flohr, A., Mayweg, A., Trainor, G., et al. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use. *Black Diamond Therapeutics Inc.* **WO 2020/068867 A1** (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/09/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM